# A Phase IV Study in Drug-Naive Patients With T2DM in China

> **NCT03344341** · PHASE4 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 304 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT03344341
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-15
- **Primary completion:** 2019-05-24
- **Final completion:** 2019-05-24
- **Target enrollment:** 304 (ACTUAL)
- **Why stopped:** Study overall progress behind of scheduled timeline. Study was terminated early due to company decision.
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344341, "A Phase IV Study in Drug-Naive Patients With T2DM in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03344341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*